Sign In
Buy CDTX
$221.38
+0 (+0%)
At Close: Apr 07, 2026
The Latest Analyst Ratings for Cidara Therapeutics
01:00pm, Thursday, 23'rd Mar 2023 Benzinga
Within the last quarter, Cidara Therapeutics (NASDAQ:CDTX) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
1
0
0
0
Cidara Therapeutics (CDTX) Reports Q4 Loss, Misses Revenue Estimates
12:35pm, Thursday, 23'rd Mar 2023 Zacks Investment Research
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -1,800% and 45.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock
Why Agile Therapeutics Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
12:03pm, Thursday, 23'rd Mar 2023 Benzinga
Gainers
ZyVersa Therapeutics, Inc. (NASDAQ: ZVSA) shares rose 82.8% to $2.98 in pre-market trading. ZyVersa Therapeutics recently reported new employment inducement grants under Nasdaq Listing Rule 5
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
11:12am, Thursday, 23'rd Mar 2023 GlobeNewswire Inc.
SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for
Cidara Therapeutics (CDTX) Reports Q4 Loss, Misses Revenue Estimates
09:54am, Thursday, 23'rd Mar 2023
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -1,800% and 45.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock
Why Is Cidara Therapeutics (CDTX) Stock Down 12% Today?
09:16am, Thursday, 23'rd Mar 2023
Cidara Therapeutics (NASDAQ: CDTX ) stock is falling on Thursday despite the immunotherapy company getting positive news from the FDA. The big FDA news is the approval of rezafungin as a treatment for
Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO™ (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis
09:23pm, Wednesday, 22'nd Mar 2023 GlobeNewswire Inc.
– REZZAYO is a novel, once-weekly, next-generation echinocandin indicated for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options –
Stocks To Watch: All Eyes On The Federal Reserve
02:30pm, Saturday, 18'th Mar 2023 Seeking Alpha
Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week.
Cidara Therapeutics Presents Preclinical Data on CD73-Targeting Drug-Fc Conjugate at the 2023 ESMO Targeted Anticancer Therapies Congress
09:15pm, Tuesday, 07'th Mar 2023 GlobeNewswire Inc.
SAN DIEGO, March 07, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for
Cidara Therapeutics Announces Closing of Public Offerings of Common Stock and Preferred Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares in Public Offering of Common Stock
09:01pm, Tuesday, 07'th Mar 2023 GlobeNewswire Inc.
SAN DIEGO, March 07, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for
Why Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
06:20pm, Friday, 03'rd Mar 2023 Benzinga
Gainers
ObsEva SA (NASDAQ: OBSV) surged 86.6% to $0.1978 after dropping over 12% on Thursday. ObsEva recently announced strategic reorganization to consolidate operations in Switzerland.
Altamira The
Cidara Therapeutics Announces Pricing of Public Offerings of Common Stock and Preferred Stock
02:14pm, Friday, 03'rd Mar 2023 GlobeNewswire Inc.
SAN DIEGO, March 03, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for
Why Heritage Insurance Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
01:24pm, Friday, 03'rd Mar 2023 Benzinga
Gainers
ObsEva SA (NASDAQ: OBSV) rose 93.1% to $0.2047 in pre-market trading after dropping over 12% on Thursday. ObsEva recently announced strategic reorganization to consolidate operations in Switz
Cidara Therapeutics Announces Underwritten Public Offerings of Common Stock and Preferred Stock
09:14pm, Thursday, 02'nd Mar 2023 GlobeNewswire Inc.
SAN DIEGO, March 02, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for
Penny Stocks To Buy: 5 To Watch Before Next Week
04:52pm, Wednesday, 01'st Mar 2023 PennyStocks
Penny stocks to watch this week.
The post Penny Stocks To Buy: 5 To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
